top of page

Scientific studies on mRNA

SARS-CoV-2 vaccine and increased myocarditis mortality risk, A population based comparative study in Japan

Myocarditis & Myopericarditis

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Myocarditis & Myopericarditis

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17, A Stratified National Database Analysis

Myocarditis & Myopericarditis

Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England.pdf

Myocarditis & Myopericarditis

Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years.

Myocarditis & Myopericarditis

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Myocarditis & Myopericarditis

Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex

Myocarditis & Myopericarditis

Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England

Excess mortality

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent

Myocarditis & Myopericarditis

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccinePericarditis tras la administración de la vacuna de ARNm BNT162b2 contra la COVID-19

Pericarditis

Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA a follow-up surveillance study.

Myocarditis & Myopericarditis

Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia A Multicenter Study

Myocarditis & Myopericarditis

Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination a population-based cohort study

Myocarditis & Myopericarditis

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

Myocarditis & Myopericarditis

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

Myocarditis & Myopericarditis

Myopericarditis After COVID-19 mRNA Vaccination Among Adolescents and Young Adults.pdf

Myocarditis & Myopericarditis

Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination

Myocarditis & Myopericarditis

Myocarditis With COVID-19 mRNA Vaccines

Myocarditis & Myopericarditis

Myocarditis Temporally Associated With

Myocarditis & Myopericarditis

Myocarditis related SARS-CoV-2 infection or vaccination an expert consensus statement on its diagnosis and management

Myocarditis & Myopericarditis
bottom of page